ProQR Therapeutics N.V.
PRQRNasdaq
$1.70
↑ +1.8%Jul 17 close · end-of-day
Price
1Y↓ -27.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
ProQR Therapeutics N.V. engages in the discovery and development of RNA-based therapeutics. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University.
- CEO
- Daniel Anton de Boer
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 180
- Website
- proqr.com
Management & directors
- De Boer Daniel AntonChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 25, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-09 | de Boer Daniel Anton· Chief Executive Officer | Buy | 150,000 | $1.74 | $261,000.00 | filing |
| 2026-07-07 | de Boer Daniel Anton· Chief Executive Officer | Buy | 150,000 | $1.59 | $238,500.00 | filing |
| 2026-06-26 | Filius Bart | Buy | 150,000 | $1.54 | $231,000.00 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.